LogicMark, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LogicMark, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.43M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $9.90M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $9.93M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.92M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $10.02M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.44M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $17.14M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $17.12M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $16.04M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $7.74M | Apr 2, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $33.5K | Apr 14, 2017 |
| FY2016 | Dec 31, 2015 | $167.2K | Apr 14, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.63M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.62M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $6.66M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.23M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $5.79M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $7.68M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $12.77M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $12.31M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $10.98M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.30M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.47M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.00M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($14.55M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.92M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($11.71M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($2.86M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($11.79M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($7.09M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($8.26M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($12.75M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.90M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($7.67M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($15.33M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.91M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($7.55M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($586.1K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.58M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $587.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.15M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($6.71M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $617.4K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $558.6K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $982.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.24M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $932.6K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.11M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $761.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $761.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $888.2K | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $2.43M | Mar 6, 2015 |
| FY2014 | Dec 31, 2013 | $835.2K | Mar 6, 2015 |
| FY2013 | Dec 31, 2012 | $220.1K | Feb 25, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.06M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($4.25M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($4.32M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.61M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($5.91M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($313.0K) | Apr 15, 2022 |
| FY2017 | Dec 31, 2017 | ($5.61M) | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | ($950.0K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($8.62M) | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | ($5.16M) | Apr 14, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.3K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $25.6K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $53.4K | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $282.5K | Mar 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.31M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $14.22M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $17.02M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $25.64M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $30.12M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $26.95M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $25.05M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $38.06M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $48.24M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $35.39M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.22M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.03M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.85M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.73M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $15.98M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $16.53M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $21.51M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $27.31M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $32.57M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.28M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $10.39M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $13.11M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $20.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $26.59M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | $9.16M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $6.71M | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $14.74M | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $19.13M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $2.82M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.14M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.14M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.14M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.96M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $10.96M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $15.48M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $15.48M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $15.48M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $15.48M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $15.48M | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($116.63M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($109.16M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($100.16M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($85.61M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($78.66M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($65.43M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($61.80M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($50.01M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($42.92M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($34.66M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.57M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.81M | Mar 27, 2026 |
| FY2023 | Dec 31, 2023 | $6.40M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $6.98M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $12.04M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.39M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.59M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $425.2K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.68M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $3.34M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2018 | $372.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $585.6K | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (10,971) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (291) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Apr 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (10,971) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (291) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 906,059 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 3,198 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 86,017 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 480,447 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 9.16M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 4.06M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 30.05M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 25.23M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 23.58M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 7.38M | Apr 2, 2018 |